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EFFECTS OF NONSTEROIDAL ANTI-INFLAMMATORY
DRUGS ON TRANSFORMING GROWTH FACTOR-β
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Nonsteroidal anti-inflammatory drugs (NSAIDs) have been reported to suppress bone
remodeling in normal and repaired bones. Our previous results indicated that ketorolac and
indomethacin suppressed proliferation, stimulated early differentiation, and induced
apoptosis in cultured osteoblasts. Transforming growth factor-β (TGF-β) has been reported
to enhance proliferation, suppress differentiation, and prevent apoptosis in osteoblasts. We
proposed that one pathway of NSAID effects on osteoblast function might be through
inhibition of the expression and/or bioactivity of TGF-β in osteoblasts. We tested the effects
of ketorolac and indomethacin on the expression of TGF-β1 mRNA and protein and the
bioactivity of TGF-β in osteoblast-enriched cultures derived from fetal calvaria. The effects
of prostaglandin E1 (PGE1) and PGE2 on TGF-β expression and bioactivity were also examined
in order to understand more about the role of prostaglandins in osteoblast function.
Simultaneously, we estimated whether these NSAID effects on osteoblasts were
prostaglandin-related. The results showed that 24-hour treatments with both PGEs and
theoretic therapeutic concentrations of ketorolac and indomethacin had no significant effects
on the levels of either transcription or translation of TGF-β or the post-translational function
of TGF-β in osteoblasts. These results suggest that NSAIDs do not affect osteoblast function
through changes in TGF-β action in osteoblasts.
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Nonsteroidal anti-inflammatory drugs (NSAIDs) are
powerful drugs that relieve pain and suppress
inflammation. However, NSAIDs have been reported
to inhibit bone repair [1–6]. Ketorolac is a potent NSAID
frequently used postoperatively. It acts by blocking
the synthesis of prostaglandins at the cyclooxygenase
pathway [7]. Our previous report indicated that
ketorolac, in a rabbit model, inhibits repair of fractured
bones and bone remodeling of intact bones [8]. We also
found that ketorolac mainly suppresses the early stage
of endochondral ossification during bone repair [9].
Our in vitro study revealed that NSAIDs inhibit
proliferation and stimulate early differentiation
through a prostaglandin-independent pathway in
osteoblast-enriched cultures [10]. These findings
© 2003 Elsevier. All rights reserved.
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suggest that the effects of NSAIDs on osteoblast
function might contribute to their suppressive effects
on bone remodeling, especially at the early stage of
endochondral ossification. However, the mechanisms
by which NSAIDs affect osteoblast function remain
unclear. This study was designed to investigate how
NSAIDs affect osteoblast function.
Transforming growth factor-β‚ (TGF-β) is abundant
in bone (200 μg/kg), and is synthesized by osteoblasts,
osteocytes, and chondrocytes [11,12]. TGF-β inhibits
bone resorption and stimulates bone formation, so it
was thought to be an important coupling factor linking
bone resorption and formation during remodeling
[13–16]. It  has also been reported to enhance
proliferation and suppress differentiation during
development in cultured osteoblasts [12]. Furthermore,
TGF-β has an anti-apoptotic effect in osteoblasts [17].
NSAIDs inhibi t  prol i ferat ion and st imulate
differentiation in osteoblast-enriched cultures derived
from fetal rat calvaria [18], and have apoptotic effects
on osteoblasts [19]. Thus, we proposed that TGF-β was
a possible factor mediating the inhibitory, stimulatory,
and/or inductive effects of NSAIDs on osteoblast
proliferation, differentiation, and/or apoptosis,
respectively. The role of TGF-β1 in bone development
and repair is better known than that of other types of
TGF-β [20–22]. In this study, we investigated whether
NSAIDs affect TGF-β1 expression and bioactivity by
examining the expression of TGF-β1 mRNA and protein
as well as TGF-β bioassay in osteoblast-enriched
cultures after treatment with serial concentrations of
ketorolac and indomethacin.
Prostaglandins, particularly prostaglandin E2
(PGE2), stimulate bone formation in vivo [23–30], but
inhibit primary osteoblast proliferation in vitro [10,31,
32 ] .  Pros tag landins  are  synthes ized  under
autoregulation in osteoblasts [33]. Previous reports
indicated that prostaglandin synthesis is blocked by
NSAIDs in bone organ cultures [34] and in primary
osteoblast cultures [10]. Some investigators propose
that the suppressive effects of NSAIDs on bone repair
result from the inhibition of prostaglandin synthesis
in bone cells [35]. However, our previous report
indicated that NSAIDs affect osteoblast function
through a prostaglandin-independent pathway [10].
In this study, the effects of prostaglandins on TGF-β
expression and bioactivity were measured to elucidate
their role on osteoblast TGF-β expression and
bioactivity. We also estimated whether the effects of
NSAIDs on TGF-β expression were related to their
inhibitory effects on prostaglandin synthesis.
MATERIALS AND METHODS
Osteoblast-enriched culture
Primary osteoblast-enriched cultures were prepared
from parietal bone obtained from 21-day fetal Sprague-
Dawley rats. The parietal bones were dissected free
from sutures and periosteal layers as previously
described [10,18]. Cells were released from bone chips
by five 20-minute sequential collagenase digestions
[36]. The last three digestions were pooled as an
osteoblast-enriched cell suspension. Osteoblast-
enriched cultures have characteristics of the osteoblast
phenotype, as confirmed by high alkaline phosphatase
expression and mineralization ability [10,18]. Cells
were plated into 24-well plates (5 x 104 cells/1.9 cm2
well), 6-well plates (1 x 105 cells/9.4 cm2 well), or 75 cm2
flasks in Dulbecco’s modified Eagle medium (DMEM)
containing 100 μg/mL L-glutamine, ascorbic acid, non-
essential amino acids, gentamicin, 1% ITS+ (aqueous
solution containing insulin, transferrin, selenous acid,
linoleic acid, and bovine serum albumin), and 10%
fetal calf serum. Cultures were incubated in 5% CO2 at
37°C and the medium was changed every 3 days.
Treatments
Osteoblasts were grown to confluence, then rinsed
and serum-deprived for 24 hours. After rinsing cultures
three times with serum-free medium, cultures were
incubated in conditioned media including ketorolac,
indomethacin, PGE1 or PGE2 for 24 hours. PGE1, PGE2
and indomethacin were initially dissolved in 95%
ethanol as stock agents. Conditioned media were
prepared by diluting stock agents with serum-free
medium to various concentrations of test agents. The
final concentration of alcohol in conditioned media
was 0.1% or less [37].
Northern blot analysis
Total RNA was extracted from osteoblasts using the
Stratagene micro-RNA isolation system (Stratagene
Cloning Systems, La Jolla, CA, USA). RNA samples
were quantified by spectrophotometry at 260 nm. The
total RNA sample in the sample buffer (50% de-ionized
formamide and 2.2 M formaldehyde) was denatured
at 65°C for 5 minutes and resolved by electrophoresis
Kaohsiung J Med Sci June 2003 • Vol 19 • No 6
J.K. Chang, L.Y. Chuang, M.L. Ho, and G.J. Wang
280
on 1.1% agarose gel. The RNA was then transferred
onto a nitrocellulose membrane and cross-linked to
the membrane using a UV cross-linker for 30 seconds.
The membrane was hybridized with 32P-labeled cDNA
probe. The TGF-β1 cDNA probe was derived from
purified plasmid DNA constructed using human TGF-β1
cDNA (phTGF-β-2, ATCC). Human TGF-β1 cDNA is
highly cross-reactive with that of rats because the TGF-β
molecule is highly conserved between species [14]. The
membrane was exposed with X-ray film (Kodak,
Rochester, NY, USA) in an autoradiographic cassette at
–70°C for 3 days. Membranes were re-probed with 1.7 kb
EcoRV-ApaL1 DNA fragments cloned from the human
β-actin cDNA as a positive control. Densitometry was
quantified using Bio-Profil image analysis software
(Vilber Lourmat, Marne, La Vallée, France).
TGF-β1 enzyme immunoassay
After 24 hours of incubation with test agent, the culture
supernatants of both control and experimental cultures
were collected for TGF-β1 enzyme immunoassay with
the human TGF-β1 Quantikine kit (R&D Systems,
Minneapolis, MN, USA). Latent TGF-β was activated
to its immunoreactive form prior to assay by
acidification with 1 N HCl and neutralization with 1.2 N
NaOH/0.5 M HEPES. Activated sample or standard
TGF-β‚ 200 μL, was added to each well pre-coated with
TGF-β1 receptor type II. After 3 hours of incubation,
the wells were washed and 200 μL of TGF-β1 conjugate
(polyclonal antibody against TGF-β1 conjugated to
horseradish peroxidase) was added and incubated for
a further 1.5 hours. After aspiration and washing,
200 μL of enzyme substrate solution (tetramethyl-
benzidine/hydrogen peroxidase) was added to each
well and incubated for 20 minutes. The reaction was
stopped with 50 μL of 2 N sulfuric acid and the wells
were  assessed at  450  nm using an enzyme
immunoassay reader. All assays were performed in
duplicate at room temperature. A standard curve was
generated by plotting the log OD (optical density) as
a function of log TGF-β1 concentration. The TGF-β1
concentration of a sample was calculated from the
standard curve.
TGF-β bioassay
The inhibitory effect of TGF-β on the proliferation of
cloned mink lung epithelial cells (CCL-64, ATCC)
reflects the bioactivity of TGF-β [38,39]. After 24 hours
of agent treatment, conditioned media were discarded
and cultures were rinsed three times with serum-free
medium. TGF-β released from osteoblasts was collected
by leaving 1 mL of serum-free medium in each well for
another 24 hours. Serum-free medium containing TGF-β
was heated at 80°C for 15 minutes to convert latent
TGF-β to its active form. Media containing active TGF-β
was transferred to subconfluent, serum-deprived mink
lung cell cultures for 24 hours, after which thymidine
incorporation by the mink lung cell cultures was
examined. To further confirm that the inhibition of
proliferation in mink lung cell cultures was attributable
to TGF-β bioactivity, thymidine incorporation by mink
lung cell cultures pre-cultivated in TGF-β neutralized
and non-neutralized osteoblast culture supernatants
were compared. Pan-specific TGF-β neutralizing
antibody (20 μg/mL; R&D Systems) was added to
neutralize TGF-β in the active TGF-β–containing
medium at 37°C for 1 hour prior to transferring to the
mink lung cell cultures.
Thymidine incorporation
Cloned mink lung cells were pulsed with 0.2 μCi/mL
[3H]thymidine 4 hours before harvest. At harvest, cells
were washed with ice-cold PBS-thymidine (phosphate-
buffered saline containing thymidine 1 μg/mL) for 5
minutes followed by 10% trichloroacetic acid (TCA)
for 15 minutes, 5% TCA for 10 minutes, and 95%
ethanol for 10 minutes. The cell layers were then
solubilized in 0.05% sodium dodecyl sulfate/0.1 N
NaOH. Aliquots of solubilized cells were mixed into
liquid scintillant and counted in a beta counter.
Statistical analysis
Data are expressed as the mean ± standard error of the
mean of four wells from representative experiments. All
experiments were repeated at least three times. Statistical
significance of the effects of ketorolac, indomethacin and
PGE2 on TGF-β1 synthesis and of NSAIDs on TGF-β
bioactivity was evaluated by the Kruskall-Wallis test
and Dunn multiple comparisons, while that of the
effects of TGF-β on thymidine incorporation was
assessed using the Mann-Whitney test.
RESULTS
TGF-β mRNA expression
The relative densities of TGF-β1/β-actin obtained from
Northern blot analysis revealed no significant
NSAID effects on TGF-β expression in osteoblasts
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differences among ketorolac- (10-7–10-4 M) and
indomethacin-treated (10-7–10-5 M) and control
osteoblast-enriched cultures (Figure 1). The results
showed that 24-hour treatment with these broad ranges
of concentrations of ketorolac and indomethacin had
no significant effect on the expression of TGF-β1 mRNA
in osteoblasts. PGE2 also had no significant effect on
the expression of TGF-β1 mRNA in osteoblast-enriched
cultures over a concentration range of 10-9–10-6 M
(Figure 2).
TGF-β1 enzyme immunoassay
TGF-β1 levels in culture supernatants were not
significantly different among ketorolac- (10-6 and 10-4 M)
and indomethacin-treated (10-6 and 10-4 M) and control
osteoblast-enriched cultures (Figure 3). Nor did PGE2
(10-8 and 10-6 M) affect TGF-β1 levels released from
cultured osteoblasts (Figure 4).
TGF-β bioassay
After osteoblast culture supernatants were neutralized
with TGF-β antibody, thymidine incorporation by mink
Figure 1. Effects of ketorolac and indomethacin on transforming
growth factor-β1 (TGF-β1) mRNA expression in osteoblast-
enriched cultures. Representative Northern blot images of TGF-β1
and β-actin from total RNA of osteoblasts. Cells were incubated
with serum-free medium (control) or conditioned media containing
various concentrations of ketorolac (Kt) or indomethacin (Indo)
for 24 hours. The densities of the bands were quantified by
densitometry. OD (TGF-β1/β-actin) = ratio of optical densities of
TGF-β1 and β-actin.
Figure 2. Effects of prostaglandin E2 (PGE2) on transforming
growth factor-β1 (TGF-β1) mRNA expression in osteoblast-
enriched cultures. Representative Northern blot images of TGF-β1
and β-actin from total RNA of osteoblasts. Cells were incubated
with serum-free medium (control) or conditioned media containing
various concentrations of PGE2 for 24 hours. The densities of the
bands were quantified by densitometry. OD (TGF-β1/β-actin) =
ratio of optical densities of TGF-β1 and β-actin.
lung cell cultures was significantly elevated regardless
of  whether  cul tures  were  pre-cul t ivated in
supernatants from control and prostaglandin- or
NSAID-treated osteoblast cultures (p < 0.01) (Figures
5 and 6). Thymidine incorporation by mink lung cell
cultures pre-cult ivated in osteoblast  culture
supernatants was significantly reduced compared with
that by cells that were not pre-cultivated in osteoblast
culture supernatants (blank control) (p < 0.01) (Figure
7). Treated and control osteoblast culture supernatants
had similar proliferation inhibitory effects to TGF-β1
(1 ng/mL) in mink lung cell cultures (Figure 7). These
results confirm that all the osteoblast cultures in these
experiments released bioactive TGF-β which inhibited
thymidine incorporation in mink lung cell cultures. In
comparison with the bioactivities of TGF-β released
from control and PGE1- (10
-8 M), PGE2- (10
-8 M),
ketorolac- (10-5 M), and indomethacin-treated (10-5 M)
osteoblast cultures, there were no significant
differences among groups (Figure 7).
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Figure 3. Effects of ketorolac and indomethacin on transforming growth factor-β1 (TGF-β1) synthesis in osteoblast-enriched cultures.
Osteoblasts were incubated with serum-free medium (control) or conditioned media containing various concentrations of ketorolac (Kt)
or indomethacin (Indo) for 24 hours. TGF-β1 secreted in culture supernatant was measured using TGF-β1 enzyme immunoassay. Each
bar represents the mean ± standard error of the mean of four replicate cultures. The assay was performed in duplicate for each culture.
Data were evaluated by the Kruskall-Wallis test.
Figure 4. Effects of prostaglandin E2 (PGE2) on transforming
growth factor-β1 (TGF-β1) synthesis in osteoblast-enriched
cultures. Osteoblasts were incubated with serum-free medium
(control) or conditioned media containing various concentrations
of PGE2  for 24 hours. TGF-β1 secreted in culture supernatant
was measured using TGF-β1 enzyme immunoassay. Each bar
represents the mean ± standard error of the mean of four replicate
cultures. The assay was performed in duplicate for each culture.
Data were evaluated by the Kruskall-Wallis test.
a prostaglandin-independent pathway. Some NSAIDs
alter the glucosaminoglycan synthesis of chondrocytes
by affecting cytokines or growth factors [40,41].
S-isomers of NSAIDs up-regulate the expressions of
interleukin-10 (IL-10) and tumor necrosis factor, and
down-regulate IL-6 in murine peritoneal macrophages
[42]. Autocrine secretion of TGF-β in osteoblasts
modulates the function of osteoblasts and osteoclasts.
Thus, TGF-β acts as an important coupling factor during
the normal bone remodeling cycle, and as a significant
growth factor stimulating bone repair [14,43]. Previous
reports have indicated that TGF-β  stimulates
proliferation, prevents apoptosis, and suppresses
differentiation of osteoblasts in vitro [12,17]. Our
previous results showed that NSAIDs suppress bone
repair in vivo as well as inhibit proliferation, stimulate
differentiation, and induce apoptosis in cultured
osteoblasts [8–10]. Accordingly, we hypothesized that
these NSAID effects occurred through inhibition of
TGF-β production and/or action in osteoblasts. In this
study, we investigated the effects of indomethacin and
ketorolac on the expressions of mRNA and protein as
well as the bioactivity of TGF-β. We tested a broad
range of concentrations of ketorolac (10-7–10-4 M) and
indomethacin (10-7–10-5 M). However, these agents
had a non-significant effect on the expression of TGF-β1
mRNA in osteoblast-enriched cultures. We also
evaluated the amount of TGF-β1 released from
osteoblast-enriched cultures after NSAID treatment
DISCUSSION
The major pathway of the anti-inflammatory and
analgesic effects of NSAIDs is to inhibit the synthesis
of prostaglandins that mediate inflammation and pain.
However, several recent reports have indicated that
some NSAIDs affect various cellular functions through
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Figure 5. Effects of transforming growth factor-β (TGF-β) released from nonsteroidal anti-inflammatory drug (NSAID)-treated
osteoblasts on thymidine incorporation by mink lung epithelial cell cultures. Osteoblasts were incubated with serum-free medium
(control) or conditioned media containing 10-5 M of ketorolac (Kt) or indomethacin (Indo) for 24 hours. Media containing TGF-β were
collected and activated. From each well, 0.5 mL of active TGF-β–containing medium was transferred into mink lung epithelial cell
cultures ( NSAIDs), while the other 0.5 mL was pre-treated with pan-specific TGF-β neutralizing antibody prior to transferring
( NSAIDs + anti-TGF-β). Each bar represents the mean ± standard error of the mean of four replicate cultures. Data were evaluated
by the Mann-Whitney test. *Thymidine uptake of cultures neutralized with anti-TGF-β antibody was significantly elevated compared
to non-neutralized cultures, p < 0.01.
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Figure 6. Effects of transforming growth factor-β (TGF-β) released from prostaglandin E (PGE)-treated osteoblasts on thymidine
incorporation in mink lung epithelial cell cultures. Osteoblasts were incubated with serum-free medium (control) or conditioned media
containing 10-8 M of PGE1 or PGE2  for 24 hours. Media containing TGF-β were collected and activated. From each well, 0.5 mL of
active TGF-β–containing medium was directly transferred into mink lung epithelial cell cultures ( prostaglandins), while the other
0.5 mL was pre-treated with pan-specific TGF-β neutralizing antibody prior to transferring ( prostaglandins + anti-TGF-β). Each
bar represents the mean ± standard error of the mean of four replicate cultures. Data were evaluated by the Mann-Whitney test.
*Thymidine uptake of cultures neutralized with anti-TGF-β antibody was significantly elevated compared to non-neutralized cultures,
p < 0.01.
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over the range of therapeutic concentrations (10-6 and
10-4 M).  Ketorolac and indomethacin did not
significantly change the total fraction (active plus
latent forms) of TGF-β1 secreted from osteoblasts,
suggesting that 24-hour treatment with therapeutic
concentrations of ketorolac and indomethacin may not
affect osteoblast TGF-β1 expression at either the
transcriptional or translational level. In order to exclude
methodologic error, the TGF-β bioassay used in this
study was carefully confirmed to reflect the bioactivity
of TGF-β released in osteoblast-enriched cultures. The
theoretic therapeutic concentration (10-5 M) of both
NSAIDs had a non-significant effect on TGF-β
bioactivities in osteoblast-enriched cultures. This
suggests that ketorolac and indomethacin may not
affect the post-translational function of TGF-β
produced by osteoblasts.
The biologic effects of TGF-β on modulation of
bone and cartilage metabolism are significant but
complicated. Some investigators indicated that TGF-β
might act on bone or cartilage directly [44–47], while
others demonstrated that TGF-β acts by stimulating
prostaglandin synthesis [16,48–50]. Ota et al showed
that PGE2 stimulated the production of hepatocyte
growth factor in human colonic fibroblast cultures
[51] .  Accordingly,  the  interact ions  between
prostaglandins and growth factors might modulate
their biologic function in various tissues. In the present
study, we investigated the effects of PGEs on TGF-β
expression and bioactivity in order to understand the
role of prostaglandins other than their direct actions
on osteoblasts. The results indicate that a broad
concentration range of PGE2 (10
-9–10-6 M) had no
significant effect on TGF-β  mRNA expression.
Treatment with PGE2 (10
-8 M and 10-6 M) did not
significantly change the amount of TGF-β1 secreted by
osteoblast-enriched cultures. PGE1 and PGE2 (10
-8 M)
showed no significant effects on the bioactivity of
TGF-β secreted from osteoblasts. Although conflicting
results of the effects of prostaglandins on TGF-β
expression and bioactivity have been reported [52],
the different sources of the cells (i.e. species of
Figure 7. Effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and prostaglandin Es (PGEs) on the bioactivities of osteoblast
transforming growth factor-β (TGF-β). Osteoblasts were incubated with serum-free medium (OB control) or conditioned media
containing 10-5 M of ketorolac (Kt) or indomethacin (Indo) or 10-8 M of PGE1 or PGE2 for 24 hours. Media containing TGF-β were
collected, activated, and then transferred into mink lung epithelial cell cultures. Thymidine incorporations of mink lung cell cultures
incubated with serum-free medium (blank control), TGF-β1, or osteoblast culture supernatants (OB control, PGE1, PGE2, Kt, or Indo)
were measured. Each bar represents the mean ± standard error of the mean of four replicated cultures. Data were evaluated by the
Kruskall-Wallis test and Dunn multiple comparisons. *Thymidine uptake of all cultures was significantly less than in blank control
cultures, p < 0.01.
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experimental animal, cell fractions collected from
enzyme digestions, etc.) or different incubation times
with agents might reveal different responses of the
cells to the agents. The findings of this study imply
that 24-hour treatment with PGEs may not modulate
the expression and bioactivity of TGF-β1 in fetal rat
calvarial osteoblasts.
NSAIDs have been reported to suppress cell
proliferation and/or to induce apoptosis in several
cell lines [53–57]. However, the possible mechanisms
have yet to be elucidated. In our previous study, 24-
hour treatment with ketorolac and indomethacin (10-7–
10-4 M) significantly inhibited osteoblast proliferation
[10]. In this study, we demonstrated that 24-hour
treatment with NSAIDs did not alter the expression or
bioactivity of TGF-β in osteoblasts, implying that the
effects of NSAIDs on osteoblast function may not be
mediated by TGF-β. A recent report indicated that
NSAIDs, by reducing the expression of vascular
endothelial growth factor, may suppress proliferation
and angiogenesis ,  and induce  apoptos is  in
gastrointestinal cancer cells [58]. Accordingly, other
anti-proliferative or anti-apoptotic growth factors
involved in bone metabolism may mediate NSAID
effects on osteoblast function. Other reports show that
NSAIDs suppress cell growth and/or induce apoptosis
in normal or tumor cells by decreasing cell-cycle
regulators (i.e. cyclins or cyclin-associated kinases)
and/or increasing pro-apoptotic proteins (i.e. bak)
[53–57]. Shiff et al reported that aspirin, indomethacin,
piroxicam, and naproxen caused cell-cycle quiescence
and apoptosis, and simultaneously reduced the levels
of p34cdc2 and p33cdk2 in colon adenocarcinoma cells
[59]. Arber et al indicated that the cell growth-inhibiting
and apoptosis-inducing effects of sulindac sulfide on
parental enterocytes may result from the reduction of
bak expression [53]. Therefore, it may be worth
investigating the mechanism of NSAID effects on
osteoblast function by studying the possible pathways
of NSAID effects on osteoblast function through
altering the cell cycle and/or apoptosis cascades.
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